Intriguingly, significant reduction in tumor burden (upwards to ~75%) was observed in both AITL and PTCL subsets that did not express CD30, and there was no correlation between CD30 expression based on immunohistochemistry and response rates. This evidence concerns the gene TNFRSF8 and angioimmunoblastic T-cell lymphoma.